Kyverna Therapeutics | LinkedIn (original) (raw)

Biotechnology Research

Emeryville, California 19,688 followers

Harnessing the power of cell therapy in autoimmune disease.

About us

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Industry

Biotechnology Research

Company size

51-200 employees

Headquarters

Emeryville, California

Type

Public Company

Founded

2018

Specialties

cell therapy, autoimmune, lupus, multiple sclerosis, systemic sclerosis, scleroderma, myasthenia gravis, CAR T-cell, and stiff-person syndrome

Locations

Employees at Kyverna Therapeutics

Updates

We’re excited to announce that Naji GEHCHAN, MD, MBA, has joined us to serve as our Chief Medical and Development Officer. Dr. Gehchan brings a wealth of U.S. and international experience to Kyverna across multiple therapeutic areas, including immunology, successfully driving complex development programs to commercialization. His leadership and drive for operational excellence will be instrumental as we urgently progress the clinical development priorities that lie ahead for the company.#CARTCellTherapy #autoimmunediseaseTo learn more: https://lnkd.in/gQJwyrEA
Happy Holidays from all of us at Kyverna!
We are pleased to welcome two industry leaders to our Kyverna team this week. Tracy Rossin joins as our new 𝗦𝗲𝗻𝗶𝗼𝗿 𝗩𝗶𝗰𝗲 𝗣𝗿𝗲𝘀𝗶𝗱𝗲𝗻𝘁 𝗼𝗳 𝗖𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝗔𝗳𝗳𝗮𝗶𝗿𝘀, 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿 𝗥𝗲𝗹𝗮𝘁𝗶𝗼𝗻𝘀 and Dan Maziasz joins as our new 𝗖𝗵𝗶𝗲𝗳 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗢𝗳𝗳𝗶𝗰𝗲𝗿. Welcome to Kyverna, Tracy and Dan!
Happy Thanksgiving from all of us at Kyverna! Today, we are incredibly grateful for every patient participating in #CARTCellTherapy clinical trials worldwide. Their courage and commitment are driving critical advancements in research and paving the way for a potential paradigm shift in the treatment of #autoimmunedisease. Thank you for being a part of this transformative journey!
👏 What an amazing experience at #ACR24! Kyverna was thrilled to join American College of Rheumatology at ACR Convergence 2024 in Washington, DC! A special shout out to all who visited our booth and attended our symposium to learn more about how we are harnessing the power of #CARTCellTherapy for #autoimmunedisease treatment. We’re already looking forward to next year in Chicago! Stay tuned for more highlights from the conference.
We’re gearing up for today’s symposium at #ACR24! Join us from 6:00-7:45pm for KYV-101 Anti-CD19 CAR T-Cell Therapy: The Future of Autoimmune Disease Treatment. Discover the latest data from Kyverna and the potential of CAR T-cell therapy for #autoimmunedisease.
We are thrilled to present the latest data update from KYV-101 in the treatment of lupus nephritis patients at #ACR24. All patients with at least six months of follow-up after treatment with KYV-101 at our target dose continue to display sustained efficacy and durability across key pillars of disease. This update further establishes KYV-101’s potential to deliver significant clinical benefit with a manageable safety profile and reinforces our clinical experience with KYV-101 in lupus nephritis and other #autoimmunedisease.
Kyverna is excited to join #ACR24 in Washington, DC with the American College of Rheumatology. Visit us at booth 2802 to learn more about how we're developing #CARTCellTherapy for patients with autoimmune diseases, designed to achieve deep B cell depletion for an immune system reset. Don’t miss our symposium on 11/18 from 6:00-7:45pm and explore the future of #autoimmunedisease treatment. See you there!

Join now to see what you are missing

Join now

Kyverna Therapeutics | LinkedIn (original) (raw)

Biotechnology Research

Emeryville, California 19,688 followers

Harnessing the power of cell therapy in autoimmune disease.

About us

Locations

Employees at Kyverna Therapeutics

Updates

Join now to see what you are missing

Similar pages

Browse jobs

Funding